Anti-Smad2 Antibody

This polyclonal reagent from Antibodies.com targets Smad2, a downstream effector in the TGF-β signaling cascade that becomes phosphorylated at its C-terminal Ser465/467 residues following type I receptor activation. The unconjugated antibody is supplied as 100 µl of polyclonal sera from immunized rabbits, validated for western blot, immunohistochemistry, immunofluorescence, and ELISA against human, mouse, and rat samples.

Smad2 partners with Smad4 to translocate into the nucleus and regulate transcription of genes controlling proliferation, differentiation, and extracellular matrix production. Researchers investigating fibrosis, epithelial-mesenchymal transition, and tumor progression use anti-Smad2 antibodies to confirm pathway engagement downstream of TGF-β ligand stimulation, compare cytoplasmic versus nuclear localization in fixed tissue, and assess total protein abundance across treatment groups. The polyclonal format offers broader epitope coverage than monoclonal alternatives, an advantage when detecting total Smad2 levels or when phospho-specific reagents are not available. Aliquot upon arrival, refrigerate between uses, and limit freeze-thaw cycles to preserve antibody activity over the product shelf life.